Hillman Richard John, Cuming Tamzin, Darragh Teresa, Nathan Mayura, Berry-Lawthorn Michael, Goldstone Stephen, Law Carmella, Palefsky Joel, Barroso Luis F, Stier Elizabeth A, Bouchard Céline, Almada Justine, Jay Naomi
1Dysplasia and Anal Cancer Services, St Vincent's Hospital, Darlinghurst; 2Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, New South Wales, Australia; 3Homerton University Hospital NHS Foundation Trust, Homerton, London, UK; 4Department of Pathology Mt. Zion Medical Center; 5Homerton Anal Neoplasia Service (HANS), London, UK; 6Anal Neoplasia Clinic, Research, and Education Center, San Francisco, CA; 7Laser Surgery Care, New York, NY; 8St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Darlinghurst, New South Wales, Australia; 9University of California-San Francisco, San Francisco, CA; 10Wake Forest Baptist Health Infectious Diseases/Internal Medicine, Winston-Salem, NC; 11Obstetrics and Gynecology, Dysplasia Services, Boston University Medical Center, Boston, MD; 12Centre Médical Berger Centre, Chemin Sainte-Foy, Québec, Canada; 13Anal Cancer Foundation, Dumbo, Brooklyn, NY; and 14UCSF ANCRE Center, Mount Zion Hospital, San Francisco, CA.
J Low Genit Tract Dis. 2016 Oct;20(4):283-91. doi: 10.1097/LGT.0000000000000256.
To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors.
After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2015, a first version was drafted and sent to key stakeholders. A complete draft was reviewed by the Board of the International Anal Neoplasia Society (IANS) and uploaded to the IANS Web site for all members to provide comments. The final draft was ratified by the IANS Board on June 22, 2016.
The essential components of a satisfactory high-resolution anoscopy (HRA) were defined. Minimum standards of service provision, basic competencies for clinicians, and standardized descriptors were established. Quality assurance metrics proposed for practitioners included a minimum of 50 HRAs per year and identifying 20 cases or more of anal high-grade squamous intraepithelial lesions (HSILs). Technically unsatisfactory anal cytological samples at first attempt in high-risk populations should occur in less than 5% of cases. Where cytological HSIL has been found, histological HSIL should be identified in ≥ 90% of cases. Duration of HRA should be less than 15 minutes in greater than 90% of cases. Problematic pain or bleeding should be systematically collected and reported by 10% or lesser of patients.
These guidelines propose initial minimum competencies for the clinical practice of HRA, against which professionals can judge themselves and providers can evaluate the effectiveness of training. Once standards have been agreed upon and validated, it may be possible to develop certification methods for individual practitioners and accreditation of sites.
确定肛管癌前病变调查中服务提供和临床实践的最低标准。
在2015年9月17日至21日于里斯本举行的国际乳头瘤病毒会议上,专家们进行了首次面对面会议后,起草了第一版并发送给主要利益相关者。国际肛管瘤形成学会(IANS)董事会对完整草案进行了审查,并上传至IANS网站供所有成员发表意见。最终草案于2016年6月22日得到IANS董事会批准。
定义了令人满意的高分辨率肛门镜检查(HRA)的基本组成部分。确立了服务提供的最低标准、临床医生的基本能力以及标准化描述词。为从业者提议的质量保证指标包括每年至少进行50次HRA,并识别出20例或更多的肛管高级别鳞状上皮内病变(HSIL)。高危人群初次尝试时技术上不满意的肛门细胞学样本应在不到5%的病例中出现。若发现细胞学HSIL,在≥90%的病例中应识别出组织学HSIL。超过90%的病例中HRA持续时间应少于15分钟。有问题的疼痛或出血应由10%或更少的患者系统收集并报告。
这些指南提出了HRA临床实践的初步最低能力要求,专业人员可据此自我评判,服务提供者可据此评估培训效果。一旦标准达成一致并得到验证,或许有可能为个体从业者制定认证方法并对机构进行认证。